Global Burden of Disease
Psoriasis is a chronic, non-contagious, painful, and disabling disease for which there is no cure and with negative impact on patients’ quality of life (QoL). It can occur at any age and is most common in the age group 50–69.
125 million people worldwide or 2-4 percent of the total population have psoriasis, according to the World Psoriasis Day consortium. More than 85% of patients receiving treatment use topical drugs and according to the National Psoriasis Foundation (NPF), itch is present in between 70 % and 90 % of psoriasis patients. Together with flaking and scaling, itching is the most burdensome symptom to patients. In addition, people living with psoriatic disease are at an elevated risk of developing other chronic and serious health conditions, including arthritis, cardiovascular diseases, metabolic syndrome, inflammatory bowel disease and depression.
Current treatment options include topicals, orals and biologics depending on severity and if Psoriatic Arthritis (PSA) is present. According to the National Psoriasis Foundation, psoriasis is defined as Mild (<3% body surface area “BSA” covered), Moderate (3%-10% BSA), or Severe (>10% BSA). Approximately 80% of patients with psoriasis can sufficiently be treated with topical therapies due to the disease being localized skin issues and most patients on systemic therapies also use topicals for spot treatment.
The total cost of psoriasis in the US is estimated to be around $35.2 billion, with $12.2 billion in incremental medical costs.
The number of people in the US and EU living with psoriasis is estimated to be around 15 million people.
For many reasons, psoriasis can be psychologically devastating. Patients’ lives become especially difficult when psoriasis is present in highly visible areas of the skin such as the face and hands.
Surveys show that patients are in need therapies that fast and effectively reduces the the plaque and itch (within 7 days) and can easily be used in daily routines. For topicals poor adherence has historically been a major problem resulting in suboptimal treatment effect in real world settings. Main reasons are that the most potent topicals that can be used longer term are greasy or difficult to apply.
To address this unmet need, MC2 Therapeutics has developed Wynzora® Cream. It is a cream-based fixed dose combination of calcipotriene (“CAL”) and betamethasone dipropionate (“BDP”) for topical treatment of plaque psoriasis, including scalp psoriasis, in adults. Its dual mode of action of CAL and BDP provides fast onset and high efficacy through targeting the hallmark cytokines IL-23 and IL-17A/F immune axis and TNF-α expression in a single product with a favourable safety profile. Wynzora® Cream is uniquely enabled by MC2’s formulation and drug delivery system PAD Technology™, allowing a convenient-to-use aqueous cream formulation.
Psoriasis Treatment guidelines:
For further information on selected treatment guidelines, please visit below links:
MC2 Therapeutics is a proud partner of the National Psoriasis Foundation (NPF). Please visit their website below for more information on psoriasis: